IRAK4降解剂治疗化脓性汗腺炎与特应性皮炎:一项1期试验
这项随机、双盲、安慰剂对照1期试验评估IRAK4降解剂KT-474(SAR444656)的安全性与耐受性,并在中重度化脓性汗腺炎(HS)和中重度特应性皮炎(AD)患者中观察药代动力学、药效动力学及临床活性;105名健康志愿者接受单次及14天每日给药,21例患者开放标签给药28天,观察到血液及皮损中IRAK4降解、炎症生物标志物下降并与皮损和症状改善相关,无药物相关感染。
要点
- KT-474在健康志愿者血液中实现IRAK4降解,单次给药600-1,600 mg后平均降低≥93%,14天每日给药50-200 mg后平均降低≥95%。
- 患者血液中达到相似IRAK4降解,且皮损中过表达的IRAK4恢复正常。
- HS和AD患者血液及皮肤疾病相关炎症生物标志物降低,并与皮损和症状改善相关,无药物相关感染。
核心结论
- KT-474在HS和AD中提供初步概念验证,需在更大规模试验中进一步确认。
研究设计与样本
- 随机、双盲、安慰剂对照1期试验,主要目标为安全性和耐受性,次要目标包括药代动力学、药效动力学及中重度HS和中重度AD患者的临床活性。
- 105名健康志愿者接受单次给药后每日给药14天,随后21例患者开放标签队列给药28天。
主要发现
- 健康志愿者血液中观察到IRAK4降解,单次给药600-1,600 mg后平均降低≥93%,14天每日给药50-200 mg后平均降低≥95%。
- 患者血液中达到相似IRAK4降解,皮损中过表达的IRAK4恢复正常。
- HS和AD患者血液及皮肤中疾病相关炎症生物标志物降低,并与皮损和症状改善相关。
- 无药物相关感染。
局限性
- 原文指出这些结果来自据其所知首个已发表的异双功能降解剂临床试验,需在更大规模试验中进一步确认KT-474在HS和AD中的概念验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Toll-like receptor-driven and interleukin-1 (IL-1) receptor-driven inflammation mediated by IL-1 receptor-associated kinase 4 (IRAK4) is involved in the pathophysiology of hidradenitis suppurativa (HS) and atopic dermatitis (AD). KT-474 (SAR444656), an IRAK4 degrader, was studied in a randomized, double-blind, placebo-controlled phase 1 trial where the primary objective was safety and tolerability. Secondary objectives included pharmacokinetics, pharmacodynamics and clinical activity in patients with moderate to severe HS and in patients with moderate to severe AD. KT-474 was administered as a single dose and then daily for 14 d in 105 healthy volunteers (HVs), followed by dosing for 28 d in an open-label cohort of 21 patients. Degradation of IRAK4 was observed in HV blood, with mean reductions after a single dose of ≥93% at 600-1,600 mg and after 14 daily doses of ≥95% at 50-200 mg. In patients, similar IRAK4 degradation was achieved in blood, and IRAK4 was normalized in skin lesions where it was overexpressed relative to HVs. Reduction of disease-relevant inflammatory biomarkers was demonstrated in the blood and skin of patients with HS and patients with AD and was associated with improvement in skin lesions and symptoms. There were no drug-related infections. These results, from what, to our knowledge, is the first published clinical trial using a heterobifunctional degrader, provide initial proof of concept for KT-474 in HS and AD to be further confirmed in larger trials. ClinicalTrials.gov identifier: NCT04772885 .
引用
- Ackerman L, Acloque G, Bacchelli S, et al. IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial. Nat Med. 2023. PMID: 37957373. doi:10.1038/s41591-023-02635-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。